메뉴 건너뛰기




Volumn 133, Issue 2, 2015, Pages 129-135

Anti-PD-1-targeted therapies focusing on lymphatic malignancies: Biological rationale, clinical challenges and opportunities

Author keywords

Chronic lymphoid leukemia; Lymphoma; Multiple myeloma; PD 1; PD L1; PD L2

Indexed keywords

PD 1 ANTIBODY; PEMBROLIZUMAB; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; CANCER ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

EID: 84923183950     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000362151     Document Type: Review
Times cited : (10)

References (61)
  • 1
    • 0023514599 scopus 로고
    • Molecular cloning of a CD28 CDNA by a high-efficiency COS cell expression system
    • Aruffo A, Seed B: Molecular cloning of a CD28 CDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 1987; 84: 8573-8577.
    • (1987) Proc Natl Acad Sci USA , vol.84 , pp. 8573-8577
    • Aruffo, A.1    Seed, B.2
  • 3
    • 84859720182 scopus 로고    scopus 로고
    • Positive and negative regulation of cellular immune responses in physiologic conditions and diseases
    • Vigano S, Perreau M, Pantaleo G, Harari A: Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012; 2012: 485781.
    • (2012) Clin Dev Immunol , vol.2012 , pp. 485781
    • Vigano, S.1    Perreau, M.2    Pantaleo, G.3    Harari, A.4
  • 4
    • 82255192901 scopus 로고    scopus 로고
    • The emerging role of CTLA4 as a cell-extrinsic regulator of T-cell responses
    • Walker LS, Sansom DM: The emerging role of CTLA4 as a cell-extrinsic regulator of T-cell responses. Nat Rev Immunol 2011; 11: 852-863.
    • (2011) Nat Rev Immunol , vol.11 , pp. 852-863
    • Walker, L.S.1    Sansom, D.M.2
  • 6
    • 84872551703 scopus 로고    scopus 로고
    • Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells
    • Wakamatsu E, Mathis D, Benoist C: Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells. Proc Natl Acad Sci USA 2013; 110: 1023-1028.
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 1023-1028
    • Wakamatsu, E.1    Mathis, D.2    Benoist, C.3
  • 9
    • 0031172446 scopus 로고    scopus 로고
    • Immunoreceptor tyrosine-based inhibition motifs
    • Vivier E, Daeron M: Immunoreceptor tyrosine-based inhibition motifs. Immunol Today 1997; 18: 286-291.
    • (1997) Immunol Today , vol.18 , pp. 286-291
    • Vivier, E.1    Daeron, M.2
  • 10
    • 0026700235 scopus 로고
    • Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
    • Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
    • (1992) EMBO J , vol.11 , pp. 3887-3895
    • Ishida, Y.1    Agata, Y.2    Shibahara, K.3    Honjo, T.4
  • 11
    • 3142688997 scopus 로고    scopus 로고
    • SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T-cell stimulation, but only receptor ligation prevents T-cell activation
    • Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T-cell stimulation, but only receptor ligation prevents T-cell activation. J Immunol 2004; 173: 945-954.
    • (2004) J Immunol , vol.173 , pp. 945-954
    • Chemnitz, J.M.1    Parry, R.V.2    Nichols, K.E.3    June, C.H.4    Riley, J.L.5
  • 12
    • 0034927194 scopus 로고    scopus 로고
    • PD-1: An inhibitory immunoreceptor involved in peripheral tolerance
    • Nishimura H, Honjo T: PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22: 265-268.
    • (2001) Trends Immunol , vol.22 , pp. 265-268
    • Nishimura, H.1    Honjo, T.2
  • 14
    • 84873534154 scopus 로고    scopus 로고
    • The role of B7 family molecules in hematologic malignancy
    • Greaves P, Gribben JG: The role of B7 family molecules in hematologic malignancy. Blood 2013; 121: 734-744.
    • (2013) Blood , vol.121 , pp. 734-744
    • Greaves, P.1    Gribben, J.G.2
  • 16
    • 84877022722 scopus 로고    scopus 로고
    • Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    • Quezada SA, Peggs KS: Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 2013; 108: 1560-1565.
    • (2013) Br J Cancer , vol.108 , pp. 1560-1565
    • Quezada, S.A.1    Peggs, K.S.2
  • 19
    • 0033180181 scopus 로고    scopus 로고
    • Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
    • Nishimura H, Nose M, Hiai H, Minato N, Honjo T: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
    • (1999) Immunity , vol.11 , pp. 141-151
    • Nishimura, H.1    Nose, M.2    Hiai, H.3    Minato, N.4    Honjo, T.5
  • 24
    • 77950283280 scopus 로고    scopus 로고
    • Tumor cell expression of programmed cell death-1 ligand-1 is a prognostic factor for malignant melanoma
    • Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y: Tumor cell expression of programmed cell death-1 ligand-1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757-1766.
    • (2010) Cancer , vol.116 , pp. 1757-1766
    • Hino, R.1    Kabashima, K.2    Kato, Y.3    Yagi, H.4    Nakamura, M.5    Honjo, T.6    Okazaki, T.7    Tokura, Y.8
  • 26
    • 70349569569 scopus 로고    scopus 로고
    • Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    • Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
    • (2009) Blood , vol.114 , pp. 1537-1544
    • Ahmadzadeh, M.1    Johnson, L.A.2    Heemskerk, B.3    Wunderlich, J.R.4    Dudley, M.E.5    White, D.E.6    Rosenberg, S.A.7
  • 29
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 37
    • 45049087313 scopus 로고    scopus 로고
    • Programmed death 1 is a marker of angioimmunoblastic Tcell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
    • Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D: Programmed death 1 is a marker of angioimmunoblastic Tcell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008; 39: 1050-1058.
    • (2008) Hum Pathol , vol.39 , pp. 1050-1058
    • Xerri, L.1    Chetaille, B.2    Serriari, N.3    Attias, C.4    Guillaume, Y.5    Arnoulet, C.6    Olive, D.7
  • 38
    • 79960318715 scopus 로고    scopus 로고
    • Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells
    • Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM: Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 2011; 17: 4232-4244.
    • (2011) Clin Cancer Res , vol.17 , pp. 4232-4244
    • Andorsky, D.J.1    Yamada, R.E.2    Said, J.3    Pinkus, G.S.4    Betting, D.J.5    Timmerman, J.M.6
  • 40
    • 84865165316 scopus 로고    scopus 로고
    • Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer
    • Ramsay AG, Clear AJ, Fatah R, Gribben JG: Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012; 120: 1412-1421.
    • (2012) Blood , vol.120 , pp. 1412-1421
    • Ramsay, A.G.1    Clear, A.J.2    Fatah, R.3    Gribben, J.G.4
  • 41
    • 79952984773 scopus 로고    scopus 로고
    • Follicular programmed death-1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma
    • Richendollar BG, Pohlman B, Elson P, Hsi ED: Follicular programmed death-1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011; 42: 552-557.
    • (2011) Hum Pathol , vol.42 , pp. 552-557
    • Richendollar, B.G.1    Pohlman, B.2    Elson, P.3    Hsi, E.D.4
  • 42
    • 74549151013 scopus 로고    scopus 로고
    • A unifying microenvironment model in follicular lymphoma: Outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages
    • Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E: A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16: 637-650.
    • (2010) Clin Cancer Res , vol.16 , pp. 637-650
    • Wahlin, B.E.1    Aggarwal, M.2    Montes-Moreno, S.3    Gonzalez, L.F.4    Roncador, G.5    Sanchez-Verde, L.6    Christensson, B.7    Sander, B.8    Kimby, E.9
  • 45
    • 85000059393 scopus 로고    scopus 로고
    • PD-1 expression defines two distinct T-cell subpopulations that differentially impact patient outcomes in follicular lymphoma
    • Yang ZZ, Grote DM, Ziesmer SC, Ansell SM: PD-1 expression defines two distinct T-cell subpopulations that differentially impact patient outcomes in follicular lymphoma. Blood 2013; 122: 366.
    • (2013) Blood , vol.122 , pp. 366
    • Yang, Z.Z.1    Grote, D.M.2    Ziesmer, S.C.3    Ansell, S.M.4
  • 47
    • 78049370405 scopus 로고    scopus 로고
    • Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
    • Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268-3277.
    • (2010) Blood , vol.116 , pp. 3268-3277
    • Green, M.R.1    Monti, S.2    Rodig, S.J.3    Juszczynski, P.4    Currie, T.5    O'donnell, E.6    Chapuy, B.7    Takeyama, K.8    Neuberg, D.9    Golub, T.R.10    Kutok, J.L.11    Shipp, M.A.12
  • 49
    • 85000190492 scopus 로고    scopus 로고
    • Interactions between PD-1 and PD-L1 and PD-L2 promote malignant B-cell growth in Waldenstrom macroglobulinemia
    • Grote DM, Ziesmer SC, Hodge LS, Price-Troska TL, Novak AJ, Yang ZZ: Interactions between PD-1 and PD-L1 and PD-L2 promote malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 2013; 122: 4334.
    • (2013) Blood , vol.122 , pp. 4334
    • Grote, D.M.1    Ziesmer, S.C.2    Hodge, L.S.3    Price-Troska, T.L.4    Novak, A.J.5    Yang, Z.Z.6
  • 50
    • 0037126021 scopus 로고    scopus 로고
    • Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 12293-12297
    • Iwai, Y.1    Ishida, M.2    Tanaka, Y.3    Okazaki, T.4    Honjo, T.5    Minato, N.6
  • 51
    • 34347400169 scopus 로고    scopus 로고
    • Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with INF-? and TLR ligands via a MYD88-, TRAF6-, and MEK-dependent pathway
    • Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B: Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with INF-? and TLR ligands via a MYD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110: 296-304.
    • (2007) Blood , vol.110 , pp. 296-304
    • Liu, J.1    Hamrouni, A.2    Wolowiec, D.3    Coiteux, V.4    Kuliczkowski, K.5    Hetuin, D.6    Saudemont, A.7    Quesnel, B.8
  • 53
    • 84878099006 scopus 로고    scopus 로고
    • Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma
    • Kearl TJ, Jing W, Gershan JA, Johnson BD: Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620-5628.
    • (2013) J Immunol , vol.190 , pp. 5620-5628
    • Kearl, T.J.1    Jing, W.2    Gershan, J.A.3    Johnson, B.D.4
  • 56
    • 49649114804 scopus 로고    scopus 로고
    • Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    • Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.
    • (2008) Clin Cancer Res , vol.14 , pp. 3044-3051
    • Berger, R.1    Rotem-Yehudar, R.2    Slama, G.3    Landes, S.4    Kneller, A.5    Leiba, M.6    Koren-Michowitz, M.7    Shimoni, A.8    Nagler, A.9
  • 57
    • 79952279943 scopus 로고    scopus 로고
    • Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma
    • abstract TPS305
    • Westin JR, Chu F, Foglietta M, Rotem-Yehudar R, Neelapu SS: Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. ASCO Meeting Abstracts, 2010, vol 28, abstract TPS305.
    • (2010) ASCO Meeting Abstracts , vol.28
    • Westin, J.R.1    Chu, F.2    Foglietta, M.3    Rotem-Yehudar, R.4    Neelapu, S.S.5
  • 59
    • 84891371901 scopus 로고    scopus 로고
    • Anti-PD-1 antibody: A new approach to treatment of lymphomas
    • Bachy E, Coiffier B: Anti-PD-1 antibody: A new approach to treatment of lymphomas. Lancet Oncol 2014; 15: 7-8.
    • (2014) Lancet Oncol , vol.15 , pp. 7-8
    • Bachy, E.1    Coiffier, B.2
  • 61
    • 84892865086 scopus 로고    scopus 로고
    • Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma
    • Jacobsen ED: Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. J Clin Oncol 2013; 31: 4268-4270.
    • (2013) J Clin Oncol , vol.31 , pp. 4268-4270
    • Jacobsen, E.D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.